Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Interventional × Bone Neoplasms × Cefazolin × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Breast Neoplasms 4 Wound Infection 2 Infections 2 Surgical Wound Infection 1 Prostatic Neoplasms 1 Laryngeal Neoplasms 1 Clinical Stage I Cutaneous Melanoma AJCC v8 1 Carcinoma, Hepatocellular 1 Bone Neoplasms 1

Interventions

Ibandronic Acid 8 Gemcitabine 8 Doxorubicin 6 Cyclophosphamide 6 Zoledronic Acid 5 Radiation 4 Nivolumab 4 Irinotecan 4 pembrolizumab 3 Vincristine 3 Temozolomide 3 Magnetic Resonance Spectroscopy 3 Ipilimumab 3 Docetaxel 3 Cisplatin 3 3-(5-fluorobenzofuran-3-yl)-4-(5-methyl-5H-(1,3)dioxolo(4,5-f)indol-7-yl)-pyrrole-2,5-dione 3 regorafenib 2 pegfilgrastim 2 Tranexamic Acid 2 Trabectedin 2 Sunitinib 2 Standard of Care 2 Radiotherapy, Intensity-Modulated 2 Radiotherapy 2 Radiosurgery 2 Proton Therapy 2 Methotrexate 2 Injections 2 Ifosfamide 2 Etoposide 2

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT01479283 2021-03-11

PARITY

McMaster University

Phase 3 Completed

Bone Neoplasms, Infections

Data powered by HemOnc (CC BY 4.0) Colophon ⚡